Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | BCHE | P06276 | 9/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752175 | 1.00 | MAOB (0.53) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL6044629 | 0.86 | CYP4F2 (0.57) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL6044633 | 0.86 | CYP4F2 (0.57) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL321092 | 0.82 | MAOB (0.62) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL30211131 | 0.80 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL21583868 | 0.80 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL2747423 | 0.80 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL2747426 | 0.80 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL25480447 | 0.79 | MAOB (0.63) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL17386027 | 0.79 | CYP4F2 (0.59) | MAOBBCHECYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | VITAE PHARMACEUTICALS, INC | 2010-11-25 | — | — | US | disclosed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2007123718-A1 | 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES | VITAE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | REN, AGTR1, AGTR2 | MAOB 492/4885BCHE 1653/4885CYP4F2 246/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | MAOB 863/4885BCHE 2008/4885CYP4F2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.